LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION
Ask a doctor about a prescription for LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION
How to use LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION
Introduction
Package Leaflet: Information for the User
Levobupivacaine Kabi 1.25 mg/ml solution for infusion EFG
Levobupivacaine hydrochloride
Read all of this leaflet carefully before you start using this medicine,because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you experience any side effects, talk to your doctor or nurse, even if they are not listed in this leaflet. See section 4.
Contents of the pack:
- What is Levobupivacaine Kabi and what is it used for
- What you need to know before you are given Levobupivacaine Kabi
- How Levobupivacaine Kabi will be given to you
- Possible side effects
- Storage of Levobupivacaine Kabi
- Contents of the pack and further information
1. What is Levobupivacaine Kabi and what is it used for
Levobupivacaine Kabi belongs to a group of medicines called local anesthetics. This type of medicine is used to numb parts of the body or to relieve pain.
Levobupivacaine Kabi solution for infusion is only for use in adults.
Levobupivacaine Kabi is used to treat pain :
- after major surgery,
- during childbirth.
2. What you need to know before you are given Levobupivacaine Kabi
Do not use Levobupivacaine Kabi:
- if you are allergic (hypersensitive) to levobupivacaine, to any other local anesthetic or to any of the other ingredients of this medicine (listed in section 6).
- if you have very low blood pressure
- to numb a part of the body by injecting Levobupivacaine Kabi intravenously.
- to relieve pain by injecting it into the area around the uterine cervix during the early stages of childbirth (paracervical block).
Warnings and precautions
Tell your doctor before you are given Levobupivacaine Kabi if you have any of the following conditions or diseases. You may need closer monitoring or a lower dose.
- if you have heart disease
- if you have a nervous system disease
- if you are weak or ill
- if you are elderly
- if you have liver disease.
Children
Do not give this medicine to children because the safety and efficacy of this medicine for the treatment of pain in children have not been established.
Using Levobupivacaine Kabi with other medicines
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines. Tell them especially if you are taking medicines for:
- irregular heartbeats (such as mexiletine)
- fungal infections (such as ketoconazole) as they may affect the metabolism of Levobupivacaine Kabi.
- asthma (such as theophylline) as they may affect how long Levobupivacaine Kabi stays in your body.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Levobupivacaine Kabi should not be given to relieve pain by injecting it into the area around the uterine cervix during childbirth (paracervical block).
The effects of Levobupivacaine Kabi on the fetus during the first stages of pregnancy are not known. Therefore, Levobupivacaine Kabi should not be used during the first three months of pregnancy, unless your doctor considers it necessary.
It is not known whether levobupivacaine passes into breast milk. However, based on experience with similar drugs, it is expected that only small amounts of levobupivacaine will pass into breast milk. Breastfeeding is therefore possible after using a local anesthetic.
Driving and using machines
The use of Levobupivacaine Kabi may have a considerable effect on your ability to drive and use machines. Do not drive or use machinery until the effects of Levobupivacaine Kabi and the effects of the surgery have worn off. Before you leave the hospital, ask your doctor or nurse if you can drive or use machines.
Levobupivacaine Kabi contains sodium
This medicine contains 3.6 mg of sodium (main component of cooking/table salt) per ml. This is equivalent to 0.18% of the maximum recommended daily intake of sodium for an adult.
3. How Levobupivacaine Kabi will be given to you
Your doctor will give you Levobupivacaine Kabi through a small tube inserted into your back (epidural). Your doctor and nurse will carefully monitor you while you are being given Levobupivacaine Kabi.
Dose
Adults:
The amount of Levobupivacaine Kabi that will be given to you and how often it will be given will depend on what it is used for and your physical condition, age, and weight. You will be given the minimum dose that achieves anesthesia in the required area. The dose will be carefully calculated by your doctor.
When Levobupivacaine Kabi is used to relieve pain during childbirth, the dose given will be carefully controlled.
Children:
Not recommended.
If you are given too much Levobupivacaine Kabi
If you are given too much Levobupivacaine Kabi, you may experience numbness of the tongue, dizziness, blurred vision, muscle contraction, severe difficulty breathing (including respiratory arrest) and even convulsions. If you notice any of these symptoms, tell your doctor immediately. In some cases, the administration of an excessive amount of Levobupivacaine Kabi may also cause low blood pressure, bradycardia or tachycardia and changes in your heart rhythm. Your doctor may give you other medicines to help stop these symptoms.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse immediately if you think you are experiencing any of the following side effects.Some of the side effects of Levobupivacaine Kabi can be serious.
Very common(may affect more than 1 in 10 people):
- feeling tired or weak, difficulty breathing, pale skin (these are all signs of anemia)
- low blood pressure
- nausea
Common(may affect up to 1 in 10 people):
- dizziness
- headache
- vomiting
- fetal distress
- back pain
- fever
- postoperative pain
Frequency not known(frequency cannot be estimated from the available data):
- severe allergic reactions (hypersensitivity) causing severe difficulty breathing, difficulty swallowing, hives, and very low blood pressure
- allergic reactions (hypersensitivity) recognizable by red and irritated skin, sneezing, excessive sweating, increased heart rate, fainting, or swelling of the face, lips, mouth, tongue, or throat
- loss of consciousness
- drowsiness
- blurred vision
- respiratory arrest
- heart block or cardiac arrest
- localized tingling
- numb tongue
- muscle weakness or tremors
- loss of control of urine and feces
- paralysis
- convulsions
- tingling, numbness, or other unusual sensation
- prolonged erection of the penis, which can be painful
- nerve disorders that may include drooping eyelids, small pupils (black center of the eye), sunken eye socket, sweating, and/or redness of one side of the face.
Bradyarrhythmia, tachyarrhythmia, and changes in heart rhythm that can be seen on an electrocardiogram (ECG) have also been reported as side effects.
In very rare cases, some side effects may occur after long-term use or may become permanent.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the Spanish Medicines and Healthcare Products Agency's Pharmacovigilance System for Human Use: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Levobupivacaine Kabi
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date is the last day of the month shown.
Your doctor will store this medicine for you.
The solution should be used immediately after opening.
Do not use this medicine if you notice particles in the solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
6. Contents of the pack and further information
Composition of Levobupivacaine Kabi
- The active substance is levobupivacaine (as hydrochloride).
Levobupivacaine Kabi 1.25 mg/ml solution for infusion:
1 ml of solution contains 1.25 mg of levobupivacaine (as hydrochloride).
Each 100 ml bag contains 125 mg of levobupivacaine as levobupivacaine hydrochloride.
Each 200 ml bag contains 250 mg of levobupivacaine as levobupivacaine hydrochloride.
- The other ingredients are water for injections, sodium chloride, and a small amount of sodium hydroxide and hydrochloric acid.
This medicine contains a known excipient with a potential effect (sodium). See section 2 for further information.
pH: 4.0 – 6.0
Osmolality: 271 – 332 mOsmol/l
Appearance and packaging
This medicine is a clear, colorless solution in a polyolefin bag with a transparent overwrap. It is supplied in packs of 5, 24, or 60 bags of 100 ml or 5, 12, or 32 bags of 200 ml of solution.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Fresenius Kabi España S.A.U
C/ Marina 16-18, 17th floor
08005-BARCELONA
Manufacturer:
HP Halden Pharma AS
Svinesundsveien 80
1788 Halden
Norway
This medicine is authorized in the Member States of the European Economic Area under the following names:
Levobupivacaine Kabi 1.25 mg/ml solution for infusion
Member State | Marketing authorization name |
Belgium | Levobupivacaïne Fresenius Kabi 1.25 mg/ml oplossing voor infusie |
France | Levobupivacaïne Kabi 1,25 mg/ml, solution pour perfusion |
Ireland | Levobupivacaine 1.25 mg/ml solution for infusion |
Italy | Levobupivacaina Kabi |
Netherlands | Levobupivacaïne Fresenius Kabi 1.25 mg/ml oplossing voor infusie |
Slovenia | Levobupivakain Kabi 1,25 mg/ml raztopina za infundiranje |
Spain | Levobupivacaina Kabi 1,25 mg/ml solución para perfusión |
United Kingdom | Levobupivacaine 1.25 mg/ml solution for infusion |
Date of last revision of this leaflet: October 2018
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/
-------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Levobupivacaine Kabi1.25 mg/ml solution for infusion EFG
Instructions for use / handling
Levobupivacaine Kabi 1.25 mg/ml solution for infusion is for single use only and should be administered via the epidural route and not intravenously. Use only if the solution is clear and the packaging is intact. Discard any unused solution.
As with all parenteral medicines, the solution/dilution should be inspected visually before use. Only clear solutions without visible particles should be used.
Validity period after dilution:
The chemical and physical stability of levobupivacaine solution for infusion has been demonstrated
- with 8.4 µg/ml of clonidine hydrochloride, 50 µg/ml of morphine sulfate, and 2 - 4 µg/ml of fentanyl citrate for 30 days at 2-8º C or 20-22º C.
- with sufentanil added at a concentration of 0.4 µg/ml for 30 days at 2-8º C or for 7 days at 20-22º C.
From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions before use are the responsibility of the user and normally should not exceed 24 hours at 2-8º C, unless the mixture has been prepared in controlled and validated aseptic conditions.
Levobupivacaine Kabi should not be mixed with other medicines except those mentioned above. Dissolution with alkaline solutions such as sodium bicarbonate may cause precipitation.
Experience with the safety of levobupivacaine treatment for more than 24 hours is limited.
Method of administration
Administration of Levobupivacaine Kabi should only be performed by a doctor who has the necessary training and experience or under their supervision.
For information on dosage, refer to the Summary of Product Characteristics.
Careful aspiration should be performed before injection to prevent intravascular injection. If toxic symptoms appear, the injection should be stopped immediately.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSIONDosage form: INJECTABLE PERFUSION, 0.625 mg/mLActive substance: levobupivacaineManufacturer: Altan Pharmaceuticals SaPrescription requiredDosage form: INJECTABLE PERFUSION, 1.25 mg/mlActive substance: levobupivacaineManufacturer: Altan Pharmaceuticals SaPrescription requiredDosage form: INJECTABLE, 5 mg/mlActive substance: levobupivacaineManufacturer: Altan Pharmaceuticals SaPrescription required
Alternatives to LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION in Poland
Online doctors for LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LEVOBUPIVACAINE KABI 1.25 mg/mL SOLUTION FOR INFUSION – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
